SABCS 2014: ECOG 1199 Trial Commentary by Dr. Sunil Verma

SABCS 2014: ECOG 1199 Trial Commentary by Dr. Sunil Verma: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer